Director Watson buys 2,919 shares of CEL SCI at $6.85 (July 25), expanding stake 358.6%; prior buy at ticker netted +2705.8% in 30 days.
Robert Eugene Watson, a company director, purchased 2,919 shares at $6.85 on 2025-07-25, increasing his total holdings from 814 to 3,733 shares—a 358.6% expansion of his pre-transaction position. His timing appears disciplined: his one prior purchase at CVM (2024-05-08) generated a 30-day return of +2705.8% and 90-day return of +2403.6%, indicating successful entry execution at this ticker in the past. The current price of $7.15 sits -82.4% from the 52-week high of $40.50, though the stock has risen +197.9% over the prior 30 days. The company remains unprofitable (net income of $-6,572,389.00 for the latest full year) with minimal quarterly revenue ($77,403.00 in the most recent quarter), placing this purchase in the context of a loss-making enterprise that has nonetheless demonstrated extreme volatility. The director's reinvestment at depressed valuations relative to recent highs, paired with his demonstrated prior success at this ticker, merit close monitoring for the conviction signal implied by position expansion.